A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
This study has been completed.
Sponsor:
Agouron Pharmaceuticals
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002169
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: May 1999
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
| Condition | Intervention | Phase |
|---|---|---|
|
Cytomegalovirus Retinitis HIV Infections |
Drug: Nelfinavir mesylate |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Primary Purpose: Treatment |
| Official Title: | A Phase II, Randomized, Placebo-Controlled Study to Determine the Effects of Viracept on the Clinical Outcome of Cytomegalovirus (CMV) Retinitis in AIDS Patients Who Are Receiving Standard Induction and Maintenance Therapy for This Infection |
Resource links provided by NLM:
Genetics Home Reference related topics:
complement factor I deficiency
MedlinePlus related topics:
HIV/AIDS
U.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
Patients must have:
- HIV infection.
- Newly diagnosed or first progression of CMV retinitis.
Exclusion Criteria
Prior Medication:
Excluded:
Prior therapy (or less than 2 weeks) with protease inhibitor other than saquinavir.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002169
Locations
| United States, California | |
| Univ of Southern California / LA County USC Med Cntr | |
| Los Angeles, California, United States, 90033 | |
| Univ of California / UCI Med Ctr | |
| Orange, California, United States, 92868 | |
| Univ of California / San Diego Treatment Ctr | |
| San Diego, California, United States, 92103 | |
| Harbor UCLA Med Ctr | |
| Torrance, California, United States, 90502 | |
| United States, District of Columbia | |
| George Washington Univ | |
| Washington, District of Columbia, United States, 20037 | |
| United States, Illinois | |
| Northwestern Univ / SOCA | |
| Chicago, Illinois, United States, 60611 | |
| United States, Texas | |
| Univ of Texas Med Branch | |
| Galveston, Texas, United States, 77555 | |
| Baylor Univ | |
| Houston, Texas, United States, 77009 | |
Sponsors and Collaborators
Agouron Pharmaceuticals
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00002169 History of Changes |
| Other Study ID Numbers: | 259A, Study 517, AG1343-517 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
AIDS-Related Opportunistic Infections Placebos Antiviral Agents |
Cytomegalovirus Retinitis Treatment Outcome Nelfinavir |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Retinitis Cytomegalovirus Retinitis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Retinal Diseases Eye Diseases |
Cytomegalovirus Infections Herpesviridae Infections DNA Virus Infections Eye Infections, Viral Eye Infections Nelfinavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on May 21, 2013